This is one of a series of BMJ summaries of new guidelines based on the best available evidence; they highlight important recommendations for clinical practice, especially where uncertainty or controversy exists.
Further information about the guidance, a list of members of the guideline development group, and the supporting evidence statements are in the full version on bmj.com.
Assessment of disease severity and impact, and when to refer for specialist care
• Assess the severity and impact of any type of psoriasis: -At first presentation -Before referral for specialist advice and at each referral point in the treatment pathway -To evaluate the efficacy of interventions.
• When assessing the disease severity in any healthcare setting, record: -The results of a static Physician's Global Assessment (the physician's assessment of disease severity, which uses the descriptions "clear," "nearly clear," "mild," "moderate," "severe," or "very severe") 8 -The patient's assessment of current disease severity, for example, with the static Patient's Global Assessment (also using the descriptions "clear," "nearly clear," "mild," "moderate," "severe," or "very severe") 8 -The body surface area affected -Any involvement of nails and of high impact or difficult to treat sites (such as the face, scalp, palms, soles, flexures, and genitals) -Any systemic upset, such as fever and malaise, which are common in unstable forms of psoriasis such as erythroderma or generalised pustular psoriasis.
• Assess the impact of any type of psoriasis on physical, psychological, and social wellbeing by asking: -What aspects of the patient's daily living are affected by the psoriasis -How the person is coping with the skin condition and if any treatments are being used -If the person needs further advice or support -If the psoriasis has an impact on mood or causes distress -If the condition has any impact on family or carers. Ask children and young people age-appropriate q uestions.
• Box 1 outlines the indications for specialist referral.
Assessment and referral for psoriatic arthritis
• Use a validated tool to assess adults for psoriatic arthritis in primary care and specialist settings; for example, the Psoriasis Epidemiological Screening Tool (PEST, see box 2). Be aware that PEST does not detect axial arthritis or inflammatory back pain. 9 • As soon as psoriatic arthritis is suspected, refer the person to a rheumatologist for assessment and advice about planning their care.
Psoriasis is a common inflammatory skin condition affecting about 1.3-2.2% of the UK population 1 and may be associated with psoriatic arthritis. 2 People with psoriasis, especially those with severe disease, are also at increased risk of cardiovascular disease, 3 diabetes, 4 and depression. 5 Psoriasis may result in functional, psychological, and social morbidity, even in people with minimal involvement (less than the equivalent of three palm areas). However, doctors, including dermatologists, often fail to appreciate the extent of this disability, 6 and many people with psoriasis are dissatisfied with their treatment. 6 Yet, highly effective and cost effective treatments are available, and improving outcomes therefore requires better assessment and management of psoriasis, including its impact on a patient's wellbeing, by healthcare professionals. This article summarises the most recent recommendations from the National Institute for Health and Clinical Excellence (NICE) on the management of psoriasis.
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Recommendations NICE recommendations are based on systematic reviews of the best available evidence and explicit consideration of cost effectiveness. When minimal evidence is available, recommendations are based on the Guideline Development Group's experience and opinion of what constitutes good practice. Evidence levels for the recommendations are in the full version of this article on b mj. com.
Principles of care
• Provide a single point of contact for people with all types of psoriasis (and their families or carers) to aid access to appropriate information and advice about the condition and the services available at each stage of the care pathway.
GUIDELINES
Assessment and management of psoriasis: summary of NICE guidance In people whose psoriasis has not responded satisfactorily to a topical treatment strategy, before changing to an alternative treatment:
• Discuss with the person whether they have any di culties with application, cosmetic acceptability, or tolerability and where relevant o er an alternative formulation If the response to the above is unsatisfactory, or they require continuous treatment to maintain control and there is serious risk of local corticosteroid induced side e ects, o er a calcineurin inhibitor* applied twice daily for up to weeks Calcineurin inhibitors should be initiated by healthcare professionals with expertise in treating psoriasis
If the above does not result in clearance, near clearance, or satisfactory control a er weeks consider:
• A di erent formulation of the potent corticosteroid (such as a shampoo or mousse) and/or • Topical agents to remove adherent scale (such as agents containing salicylic acid, emolients, and oils) before application of the potent corticosteroid 
Systemic non-biological therapy
• Box 4 outlines when to escalate to systemic nonbiological therapy.
Choice of drugs
• Offer methotrexate as the first choice of systemic agent for people who fulfil the criteria for systemic therapy, except when contraindicated because of safety concerns or in those who meet the criteria for ciclosporin (see below).
• Offer ciclosporin as the first choice of systemic agent for people who fulfil the criteria for systemic therapy and who: -Need rapid or short term disease control (for example, a psoriasis flare) or -Have palmoplantar pustulosis or -Are considering conception (both men and women) and systemic therapy cannot be avoided.
Overcoming barriers
In primary care the main barrier to successful implementation of this guidance is likely to be insufficient training or understanding about psoriasis among healthcare professionals, since dermatology training is not compulsory. 12 Formal assessment of psoriasis-including its impact on wellbeing and identification of psoriatic arthritis and cardiovascular risk-may represent a substantial shift in approach. Both patients and professionals alike will need to be knowledgeable about where, when, and how to use topical treatments, particularly corticosteroids, to achieve effective disease control and minimise risk of adverse effects. Increasing awareness of psoriasisspecific steroid safety issues (such as which preparations contain "hidden" steroids) is also necessary. The forthcoming quality standards and implementation tools to be developed will support this.
There is no nationally managed clinical network for phototherapy in England and Wales (in contrast to Scotland 13 ), and thus no means of recording the cumulative phototherapy dose, a critical indicator of skin cancer risk, so this will require development.
Contributors: ES and CHS drafted the article. All authors revised it critically for important intellectual content and approved the final version to be published. All authors are guarantors of this article. -Patients aged ≥18 years using potent or very potent steroids -Patients aged <18 years using any potency of steroid Healthcare associated infection represents a major burden for critically ill patients; a recent point prevalence survey by the Health Protection Agency observed that 23.4% of patients in intensive care units had evidence of a healthcare associated infection. 1 Ventilator associated pneumonia remains the leading cause of nosocomial infection in this population, and, although recent estimates of attributable mortality (5-10%) are lower than previously thought, length of stay and treatment costs are substantially increased. 2 3 Colonisation of the oropharynx with enteric bacteria is considered a key step in the development of ventilator associated pneumonia and offers a potential site for intervention with oropharyngeal decontamination.
Selective digestive decontamination involves the administration of topical, non-absorbable antibiotics to the oropharynx and stomach via a nasogastric tube in combination with parenteral antimicrobials to reduce the burden of potentially pathogenic bacteria in the aerodigestive tract. Some studies have focused on decontamination strategies limited to the oropharynx alone (selective oral decontamination), avoiding enteral and intravenous antibiotics. Selective digestive decontamination was first used for immunocompromised haematology patients, but this intervention has been extensively studied in intensive care units over the past three decades. However, many clinicians remain sceptical as to whether this evidence is applicable to different healthcare systems, which vary according to environment and antibiotic resistance rates, and their own clinical practice.
What is the evidence of uncertainty?
A search of PubMed, the Cochrane Library, and Embase identified nine published meta-analyses on the topic of selective digestive decontamination in intensive care patients. The most recent was an updated Cochrane review in 2009, which identified 36 randomised clinical trials involving 6914 patients. 4 However the largest study of selective digestive decontamination 5 was not included on the basis that the cluster design prevented individual patient randomisation. 4 The odds ratio for death was 0.75 (95% confidence interval 0.65 to 0.87) with a number needed to treat of 18, although none of the individual studies was adequately powered to detect a reduction in mortality. Results for reducing ventilator associated pneumonia were more impressive, with an odds ratio of 0.28 (0.2 to 0.38) and a number needed to treat of only four. 4 With around 140 000 admissions to UK intensive care units each year, this implies there is the potential to save upwards of 7700 lives annually with this intervention, in addition to cost savings as a consequence of reduced length of stay from lower rates of ventilator associated pneumonia.
Despite this evidence, uptake of selective digestive decontamination has been poor in the UK and elsewhere. In a survey of 193 UK intensive care units, only 10 units used any form of selective digestive decontamination and just three used it in all mechanically ventilated patients. 6 Major reasons cited for avoiding this therapy were a lack of evidence (51%), fear of antibiotic resistance (47%), and failure of approval by therapeutic boards or pharmacy departments (22%). In 12% of respondents there was also a belief that microbiologists within hospitals would not support it.
Until recently no study had been adequately powered to show a mortality benefit. In a cluster randomised crossover study in 13 intensive care units in the Netherlands (excluded from the recent Cochrane review 4 ) a compari-son was made between selective digestive decontamination (including four days of intravenous cefotaxime), selective oral decontamination, and standard care, with a primary outcome measure of 28 day mortality in 5939 patients. 5 All patients with an expectation of mechanical ventilation for more than 48 hours or an intensive care unit stay more than 72 hours were included. All the units used each of the three treatment regimens for six month periods, with the order of interventions being randomised. Mortality associated with standard care was 27.5% and was reduced significantly by 3.5% with selective digestive decontamination (relative reduction 13%) and by 2.9% with selective oral decontamination (relative reduction 11%). During the periods of selective digestive decontamination and selective oral decontamination, defined daily doses of systemic antibiotics were not higher than they were with standard care, and acquisition rates for antibiotic resistant, Gram negative bacteria were significantly lower, even for bacteria resistant to the antibiotics used in selective digestive decontamination. 7 No increase in the detection of Clostridium difficile toxin was observed.
This multicentre cluster randomised crossover study 5 seems to address the two major concerns among UK intensive care physicians-those of efficacy and emergence of antibiotic resistance. Nevertheless, several important caveats would support the uncertainty expressed by physicians. Although mortality was reduced, this was not measured beyond 28 days, and it is unknown if this benefit persists or is even reversed over a longer time. A prospective randomised clinical trial of selective digestive decontamination undertaken between two intensive care units at a single institution in the Netherlands reported a relative risk of 0.65 for death in the unit using selective digestive decontamination compared with the one using standard care (95% confidence interval 0.49 to 0.85, P=0.002). However, in this study follow-up extended beyond 28 days to hospital discharge, and this reduction in relative risk narrowed to 0.78 (0.63 to 0.96, P=0.02) for hospital mortality.
In this respect it is notable that in a prospective observational study (a substudy of the Dutch multicentre crossover study 5 ) patients receiving selective digestive decontamination or selective oral decontamination had a tendency towards more healthcare associated infection after discharge from intensive care compared with standard care. 8 This observation may be related to changes in colonisation with antibiotic resistant Gram negative bacteria, which increases after cessation of selective oral decontamination and selective digestive decontamination. 9 The effects of selective digestive decontamination on antibiotic resistance may also vary according to ecological levels of resistance within an intensive care unit population. Intensive care units in the Netherlands, where many of the studies on selective digestive decontamination have taken place, have low rates of antibiotic resistance, and it is unknown whether similar effects will be observed in healthcare systems with higher levels of antibiotic resistance. Indeed, some data suggest that selective digestive decontamination can increase colonisation rates with resistant bacteria in some intensive care units, including resistant Gram positive organisms such as meticillin resistant Staphylococcus aureus (MRSA) and vancomycin resistant enterococci. 10 11 Finally, as there was no significant difference in mortality between selective oral decontamination and selective digestive decontamination in Dutch patients, 5 systemic and enteral antibiotic administration might be unnecessary. Indeed a meta-analysis of oral decontamination that included 11 randomised clinical trials enrolling 4242 patients concluded that oral antiseptics such as chlorhexidine were effective at reducing ventilator associated pneumonia.
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Is ongoing research likely to provide an answer? By searching www.controlled-trials.com and PubMed (for published trial protocols) and contacting trialists, we identified two studies likely to address the areas of uncertainty. The SuDDICU project is using case studies, questionnaires, and a Delphi survey to identify the barriers to implementation of selective digestive decontamination in the UK, Canada, Australia, and New Zealand. 13 Its results will help to guide implementation measures or the design of a controlled trial. The R-GNOSIS group (resistance in Gram negative organisms: studying intervention strategies) is planning a cluster randomised clinical trial across Europe in countries with higher (though not endemic) levels of microbiological drug resistance. 14 This study will compare standard care, selective digestive decontamination (without systemic antibiotics), selective oral decontamination, and oral decontamination with chlorhexidine in all intensive care unit patients for six month periods, with specific emphasis on the applicability of the intervention in a wider range of healthcare systems and longer term ecological effects on antibiotic resistance.
What should we do in light of the uncertainty?
Selective digestive decontamination seems to be a beneficial strategy for reducing healthcare associated infection in critically ill patients where low levels of antibiotic resistant bacteria exist within an intensive care unit population. 4 5 In healthcare systems with higher rates of antibiotic resistance clinicians should be cautious about embracing this intervention outside of well designed cluster randomised clinical trials, as there is uncertainty over the longer term benefits and ecological effects on drug resistant bacteria.
Decontamination of the oropharynx with antiseptics such as chlorhexidine seems to offer a safe and effective alternative across a variety of healthcare systems, although this intervention has never been directly 
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